Application of nanomedicines targeting non-glucose nutrients in tumor starvation therapy

LI Zhiyan; LI Xianghui; AI Shichao; YIN Yi; LIU Song; GUAN Wenxian

doi:10.11665/j.issn.1000-5048.20220402

Journal of China Pharmaceutical University > 2022 > 53(4): 392-399. > DOI: 10.11665/j.issn.1000-5048.20220402

LI Zhiyan, LI Xianghui, AI Shichao, YIN Yi, LIU Song, GUAN Wenxian. Application of nanomedicines targeting non-glucose nutrients in tumor starvation therapy[J]. Journal of China Pharmaceutical University, 2022, 53(4): 392-399. DOI: 10.11665/j.issn.1000-5048.20220402

Citation:

PDF (1435 KB)

Application of nanomedicines targeting non-glucose nutrients in tumor starvation therapy

Department of Gastrointestinal Surgery, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China

Funds: This study was supported by the National Natural Science Foundation of China (No.82172645); the Natural Science Foundation of Jiangsu Province (No.BK20200052); and the Major Project of Nanjing Health Commission (No.ZKX21013)

More Information

Received Date: March 29, 2022
Revised Date: May 25, 2022

Graphical Abstract

Abstract

Abstract

Starvation therapy is an emerging oncological treatment that targets the abnormally elevated nutrient uptake and metabolic pathways to inhibit and kill tumors. In addition to glucose, the targets of starvation therapy also include other nutrients in tumor cells.However, concerns like ineffective targeting and drug tolerance probably have an impact on their clinical translation.Nanomaterial-assisted starvation treatment has been developing quickly in recent years to address these concerns.In this review, several exemplary nanomedicines for starvation therapy and combined starvation therapy with other therapies were offered.They target nutrients other than glucose metabolism, including lactic acid, amino acids, and lipids, using nanomaterials to improve the efficacy of starvation therapy.This review provides reference for further development of nanomedicines with starvation treatment effect.
- nanomedicine,
- starvation therapy,
- cancer metabolism,
- combined therapy

FullText(HTML)

References (51)

References

[1]	. Nat Rev Cancer，2021，21（3）：162-180.
[2]	Martinez-Outschoorn UE，Peiris-Pagés M，Pestell RG，et al. Cancer metabolism：a therapeutic perspective［J］. Nat Rev Clin Oncol，2017，14（1）：11-31.
[3]	Vander Heiden MG，DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology［J］. Cell，2017，168（4）：657-669.
[4]	Chang CH，Qiu J，O'Sullivan D，et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression［J］. Cell，2015，162（6）：1229-1241.
[5]	Sun LC，Suo CX，Li ST，et al. Metabolic reprogramming for cancer cells and their microenvironment：beyond the Warburg effect［J］. Biochim Biophys Acta Rev Cancer，2018，1870（1）：51-66.
[6]	Chung BL，Toth MJ，Kamaly N，et al. Nanomedicines for endothelial disorders［J］. Nano Today，2015，10（6）：759-776.
[7]	Duraj T，Carrión-Navarro J，Seyfried TN，et al. Metabolic therapy and bioenergetic analysis：the missing piece of the puzzle［J］. Mol Metab，2021，54：101389
[8]	Kennedy KM，Scarbrough PM，Ribeiro A，et al. Catabolism of exogenous lactate reveals it as a legitimate metabolic substrate in breast cancer［J］. PLoS One，2013，8（9）：e75154.
[9]	Baltazar F，Afonso J，Costa M，et al. Lactate beyond a waste metabolite：metabolic affairs and signaling in malignancy［J］. Front Oncol，2020，10：231.
[10]	Certo M，Tsai CH，Pucino V，et al. Lactate modulation of immune responses in inflammatory versus tumour microenvironments［J］. Nat Rev Immunol，2021，21（3）：151-161.
[11]	Reinfeld BI，Madden MZ，Wolf MM，et al. Cell-programmed nutrient partitioning in the tumour microenvironment［J］. Nature，2021，593（7858）：282-288.
[12]	Cha YJ，Kim ES，Koo JS. Amino acid transporters and glutamine metabolism in breast cancer［J］. Int J Mol Sci，2018，19（3）：907.
[13]	Chen CL，Hsu SC，Ann DK，et al. Arginine signaling and cancer metabolism［J］. Cancers，2021，13（14）：3541.
[14]	Altman BJ，Stine ZE，Dang CV. From Krebs to clinic：glutamine metabolism to cancer therapy［J］. Nat Rev Cancer，2016，16（11）：749.
[15]	van Trimpont M，Peeters E，de Visser Y，et al. Novel insights on the use of L-asparaginase as an efficient and safe anti-cancer therapy［J］. Cancers，2022，14（4）：902.
[16]	Boroughs LK，DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth［J］. Nat Cell Biol，2015，17（4）：351-359.
[17]	Mulvihill MM，Nomura DK. Therapeutic potential of monoacyl glycerol lipase inhibitors［J］. Life Sci，2013，92（8/9）：492-497.
[18]	Cheng CM，Geng F，Cheng X，et al. Lipid metabolism reprogramming and its potential targets in cancer［J］. Cancer Commun （Lond），2018，38（1）：27.
[19]	Yu JT，Wei ZX，Li Q，et al. Advanced cancer starvation therapy by simultaneous deprivation of lactate and glucose using a MOF nanoplatform［J］. Adv Sci （Weinh），2021，8（19）：e2101467.
[20]	Bauer JA，Zámocká M，Majtán J，et al. Glucose oxidase，an enzyme “ferrari”：its structure，function，production and properties in the light of various industrial and biotechnological applications［J］. Biomolecules，2022，12（3）：472.
[21]	Lin LS，Song JB，Song L，et al. Simultaneous Fenton-like ion delivery and glutathione depletion by MnO 2-based nanoagent to enhance chemodynamic therapy［J］. Angew Chem Int Ed Engl，2018，57（18）：4902-4906.
[22]	Tian ZM，Yang KL，Yao TZ，et al. Catalytically selective chemotherapy from tumor-metabolic generated lactic acid［J］. Small，2019，15（46）：e1903746.
[23]	Zhou X，Zhao W，Wang MX，et al. Dual-modal therapeutic role of the lactate oxidase-embedded hierarchical porous zeolitic imidazolate framework as a nanocatalyst for effective tumor suppression［J］. ACS Appl Mater Interfaces，2020，12（29）：32278-32288.
[24]	Sun YX，Zhao DY，Wang G，et al. Recent progress of hypoxia-modulated multifunctional nanomedicines to enhance photodynamic therapy：opportunities，challenges，and future development［J］. Acta Pharm Sin B，2020，10（8）：1382-1396.
[25]	Qin XH，Zhang MZ，Hu X，et al. Nanoengineering of a newly designed chlorin e6 derivative for amplified photodynamic therapy via regulating lactate metabolism［J］. Nanoscale，2021，13（27）：11953-11962.
[26]	de Lázaro I，Mooney DJ. Obstacles and opportunities in a forward vision for cancer nanomedicine［J］. Nat Mater，2021，20（11）：1469-1479.
[27]	Tang J，Meka AK，Theivendran S，et al. Openwork@Dendritic mesoporous silica nanoparticles for lactate depletion and tumor microenvironment regulation［J］. Angew Chem Int Ed Engl，2020，59（49）：22054-22062.
[28]	Wang JW，Chen QW，Luo GF，et al. A self-driven bioreactor based on bacterium-metal-organic framework biohybrids for boosting chemotherapy via cyclic lactate catabolism［J］. ACS Nano，2021：2021Nov6.
[29]	Jiang YP，Tan YL，Xiao KF，et al. pH-regulating nanoplatform for the "double channel chase" of tumor cells by the synergistic cascade between chlorine treatment and methionine-depletion starvation therapy［J］. ACS Appl Mater Interfaces，2021，13（46）：54690-54705.
[30]	Chu Q，Zhu HM，Liu B，et al. Delivery of amino acid oxidase via catalytic nanocapsules to enable effective tumor inhibition［J］. J Mater Chem B，2020，8（37）：8546-8557.
[31]	Scalise M，Galluccio M，Console L，et al. The human SLC7A5 （LAT1）：the intriguing histidine/large neutral amino acid transporter and its relevance to human health［J］. Front Chem，2018，6：243.
[32]	Na??cz KA. Amino acid transporter SLC6A14 （ATB^0，+）— A target in combined anti-cancer therapy［J］. Front Cell Dev Biol，2020，8：594464.
[33]	Kou LF，Jiang XY，Tang YY，et al. Resetting amino acid metabolism of cancer cells by ATB^0，+-targeted nanoparticles for enhanced anticancer therapy［J］. Bioact Mater，2021，9：15-28.
[34]	Fhu CW，Ali A. Fatty acid synthase：an emerging target in cancer［J］. Molecules，2020，25（17）：3935.
[35]	Hill TK，Davis AL，Wheeler FB，et al. Development of a self-assembled nanoparticle formulation of orlistat，nano-ORL，with increased cytotoxicity against human tumor cell lines［J］. Mol Pharm，2016，13（3）：720-728.
[36]	Adeel M，Saorin G，Boccalon G，et al. A carrier free delivery system of a monoacylglycerol lipase hydrophobic inhibitor［J］. Int J Pharm，2022，613：121374.
[37]	Cao SW，Saw PE，Shen Q，et al. Reduction-responsive RNAi nanoplatform to reprogram tumor lipid metabolism and repolarize macrophage for combination pancreatic cancer therapy［J］. Biomaterials，2022，280：121264.
[38]	Huang XY，Lu Y，Guo MX，et al. Recent strategies for nano-based PTT combined with immunotherapy：from a biomaterial point of view［J］. Theranostics，2021，11（15）：7546-7569.
[39]	Giacomini I，Gianfanti F，Desbats MA，et al. Cholesterol metabolic reprogramming in cancer and its pharmacological modulation as therapeutic strategy［J］. Front Oncol，2021，11：682911.
[40]	Subramanian C，Kuai R，Zhu Q，et al. Synthetic high-density lipoprotein nanoparticles：a novel therapeutic strategy for adrenocortical carcinomas［J］. Surgery，2016，159（1）：284-294.
[41]	Yang S，Damiano MG，Zhang H，et al. Biomimetic，synthetic HDL nanostructures for lymphoma［J］. Proc Natl Acad Sci U S A，2013，110（7）：2511-2516.
[42]	Singh A，Nandwana V，Rink JS，et al. Biomimetic magnetic nanostructures：a theranostic platform targeting lipid metabolism and immune response in lymphoma［J］. ACS Nano，2019，13（9）：10301-10311.
[43]	Yang R，Fang XL，Zhen Q，et al. Mitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN［J］. Colloids Surf B Biointerfaces，2019，182：110405.
[44]	Souchek JJ，Davis AL，Hill TK，et al. Combination treatment with orlistat-containing nanoparticles and taxanes is synergistic and enhances microtubule stability in taxane-resistant prostate cancer cells［J］. Mol Cancer Ther，2017，16（9）：1819-1830.
[45]	Cheon DJ，Orsulic S. Mouse models of cancer［J］. Annu Rev Pathol，2011，6：95-119.
[46]	Boroughs LK，DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth［J］. Nat Cell Biol，2015，17（4）：351-359.
[47]	Wang M，Wang DM，Chen Q，et al. Recent advances in glucose-oxidase-based nanocomposites for tumor therapy［J］. Small，2019，15（51）：e1903895.
[48]	Chen QW，Wang JW，Wang XN，et al. Inhibition of tumor progression through the coupling of bacterial respiration with tumor metabolism［J］. Angew Chem Int Ed Engl，2020，59（48）：21562-21570.
[49]	Wang X，Zhao YB，Shi L，et al. Tumor-targeted disruption of lactate transport with reactivity-reversible nanocatalysts to amplify oxidative damage［J］. Small，2021，17（20）：e2100130.
[50]	Qi HZ，Wang Y，Yuan XB，et al. Selective extracellular arginine deprivation by a single injection of cellular non-uptake arginine deiminase nanocapsules for sustained tumor inhibition［J］. Nanoscale，2020，12（47）：24030-24043.
[51]	Corbet C，Ragelle H，Pourcelle V，et al. Delivery of siRNA targeting tumor metabolism using non-covalent PEGylated chitosan nanoparticles：identification of an optimal combination of ligand structure，linker and grafting method［J］. J Control Release，2016，223：53-63.

Cited By

Get Citation

PDF

XML

Article views (243) PDF downloads (485)

Turn off MathJax

Article Contents

Abstract

References

Application of nanomedicines targeting non-glucose nutrients in tumor starvation therapy

Abstract

References

Catalog

Export File

Citation

Format

Content